Derivatives of 7-fluoro-8-chloro-5H-dibenzo [B,E,] [1,4] diazepine and use thereof
AssigneeValentek LLC
InventorsMaksim E. Zapolski, Margarita A. Morozova, Allan G. Beniashvili
Life of this patent
Estimating the term…
Abstract
This present disclosure generally relates to medicine, and in particular to pharmacology and psychiatry, and discloses active agents and related methods of treatment which can be used for the treatment of treatment-resistant forms of schizophrenia. In some exemplary aspects, such treatments allow for eliminating both the positive and negative symptoms of schizophrenia, and cognitive disorders, without causing severe side effects that limit their use, such as sedation, tachycardia, orthostatism, agranulocytosis and sialorrhea.
Claims8
A method of treating a treatment-resistant form of schizophrenia, comprising:
- administering a therapeutically effective amount of a pharmaceutical composition to a subject in need thereof, wherein the pharmaceutical composition comprises an active ingredient selected from the group consisting of:
- (a) 11-(piperazine-1-yl)-7-fluoro-8-chloro-5H-dibenzo[b,e][1,4]diazepine;
- (b) 11-(4-methyl piperazine-1-yl)-7-fluoro-8-chloro-5H-dibenzo[b,e][1,4]diazepine;
- and (c) a pharmaceutically acceptable salt, hydrate, or solvate of (a) or (b);
- and
- reducing one or more symptoms associated with schizophrenia, wherein said symptoms comprise symptoms of a cognitive disorder;
- wherein the therapeutically effective amount comprises a daily dosage of 50 to 300 mg of the active ingredient.
Dependencies are inferred from the claim text.